Biotek-snakken — Marts 2020
-
Hansa Biopharma announces long term follow-up data that demonstrates 2-year graft survival of 89% after imlifdase treatment and transplantation.
https://www.proinvestor.com/?p=debat_1&postid=82339&thread=50&start=#82351 -
BIOTEKAKTIER KAN FORGYLDES AF AMERIKANSK BLÅSTEMPLING
Medvind fra de amerikanske lovgivere kan betyde aktieafkast og reducerede risici i biotekaktier, vurderer kapitalfond. I november blev Orphazyme blåstempelet i USA, og siden er selskabets
aktie steget med 94,2 pct. -
Hansa stiger pænt på pressemeddelelsen i dag.
-

-
-
Kunne se ud til at Gilead's Remdesivir bliver første på markedet mod Corona virus. https://m.firstwordpharma.com/analysts-give-gileads-remdesivir-50-chance-success-covid-19-treatment
-
-
-
-

-
Ny storaktionærer i Hansa Biopharma: https://www.aktiespararna.se/analysguiden/article/726483
-
Test.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind